BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koyanagi T, Saga Y, Takahashi Y, Suzuki Y, Suzuki M, Sato Y. Downregulation of vasohibin-2, a novel angiogenesis regulator, suppresses tumor growth by inhibiting angiogenesis in endometrial cancer cells. Oncol Lett 2013;5:1058-62. [PMID: 23426782 DOI: 10.3892/ol.2013.1119] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Kang Z, Ji Y, Zhang G, Qu Y, Zhang L, Jiang W. Ponatinib attenuates experimental pulmonary arterial hypertension by modulating Wnt signaling and vasohibin-2/vasohibin-1. Life Sci 2016;148:1-8. [PMID: 26860892 DOI: 10.1016/j.lfs.2016.02.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
2 Wang W, Wang Y, Chen F, Zhang M, Jia R, Liu X, Zhang C, Shao J, Cheng N, Ma G, Zhu Z, Miao Q, Liang Z. Intravenous leiomyomatosis is inclined to a solid entity different from uterine leiomyoma based on RNA-seq analysis with RT-qPCR validation. Cancer Med 2020;9:4581-92. [PMID: 32372565 DOI: 10.1002/cam4.3098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Tan X, Liao Z, Zou S, Ma L, Wang A. VASH2 Promotes Cell Proliferation and Resistance to Doxorubicin in Non-Small Cell Lung Cancer via AKT Signaling. Oncol Res 2020;28:3-11. [PMID: 30940294 DOI: 10.3727/096504019X15509383469698] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
4 Tu M, Lu C, Lv N, Wei J, Lu Z, Xi C, Chen J, Guo F, Jiang K, Li Q, Wu J, Song G, Wang S, Gao W, Miao Y. Vasohibin 2 promotes human luminal breast cancer angiogenesis in a non-paracrine manner via transcriptional activation of fibroblast growth factor 2. Cancer Letters 2016;383:272-81. [DOI: 10.1016/j.canlet.2016.09.031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
5 Koyanagi T, Suzuki Y, Saga Y, Machida S, Takei Y, Fujiwara H, Suzuki M, Sato Y. In vivo delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer. Cancer Sci 2013;104:1705-10. [PMID: 24118388 DOI: 10.1111/cas.12297] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
6 Tu M, Li Z, Liu X, Lv N, Xi C, Lu Z, Wei J, Song G, Chen J, Guo F, Jiang K, Wang S, Gao W, Miao Y. Vasohibin 2 promotes epithelial-mesenchymal transition in human breast cancer via activation of transforming growth factor β 1 and hypoxia dependent repression of GATA-binding factor 3. Cancer Lett 2017;388:187-97. [PMID: 27867016 DOI: 10.1016/j.canlet.2016.11.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
7 Liu T, Du X, Sheng X. Gene expression changes after ionizing radiation in endothelial cells derived from human endometrial cancer-preliminary outcomes. Arch Gynecol Obstet 2014;289:1315-23. [PMID: 24385285 DOI: 10.1007/s00404-013-3136-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
8 Masuda K, Tanabe K, Ujike H, Hinamoto N, Miyake H, Tanimura S, Sugiyama H, Sato Y, Maeshima Y, Wada J. Deletion of pro-angiogenic factor vasohibin-2 ameliorates glomerular alterations in a mouse diabetic nephropathy model. PLoS One 2018;13:e0195779. [PMID: 29641565 DOI: 10.1371/journal.pone.0195779] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
9 Koyanagi T, Suzuki Y, Komori K, Saga Y, Matsubara S, Fujiwara H, Sato Y. Targeting human vasohibin-2 by a neutralizing monoclonal antibody for anti-cancer treatment. Cancer Sci 2017;108:512-9. [PMID: 28032401 DOI: 10.1111/cas.13149] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
10 Tanabe K, Wada J, Sato Y. Targeting angiogenesis and lymphangiogenesis in kidney disease. Nat Rev Nephrol 2020;16:289-303. [PMID: 32144398 DOI: 10.1038/s41581-020-0260-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
11 Qu Y, Zhang G, Ji Y, Zhua H, Lv C, Jiang W. Protective role of gambogic acid in experimental pulmonary fibrosis in vitro and in vivo. Phytomedicine 2016;23:350-8. [DOI: 10.1016/j.phymed.2016.01.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
12 Hara H, Ozawa S, Ninomiya Y, Yamamoto M, Ogimi M, Nabeshima K, Nakamura K, Kajiwara H, Nakamura N, Sato Y. Prognostic significance of vasohibin-1 and vasohibin-2 immunohistochemical expression in gastric cancer. Surg Today 2020;50:1530-43. [PMID: 32494966 DOI: 10.1007/s00595-020-02040-4] [Reference Citation Analysis]
13 Okuyama M, Uchida HA, Hada Y, Kakio Y, Otaka N, Umebayashi R, Tanabe K, Fujii Y, Kasahara S, Subramanian V, Daugherty A, Sato Y, Wada J. Exogenous Vasohibin-2 Exacerbates Angiotensin II-Induced Ascending Aortic Dilation in Mice. Circ Rep 2019;1:155-61. [PMID: 33693132 DOI: 10.1253/circrep.CR-19-0008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Du H, Zhao J, Hai L, Wu J, Yi H, Shi Y. The roles of vasohibin and its family members: Beyond angiogenesis modulators. Cancer Biol Ther 2017;18:827-32. [PMID: 28886304 DOI: 10.1080/15384047.2017.1373217] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
15 Suzuki Y, Kitahara S, Suematsu T, Oshima M, Sato Y. Requisite role of vasohibin-2 in spontaneous gastric cancer formation and accumulation of cancer-associated fibroblasts. Cancer Sci 2017;108:2342-51. [PMID: 28960674 DOI: 10.1111/cas.13411] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
16 Rynkeviciene R, Simiene J, Strainiene E, Stankevicius V, Usinskiene J, Miseikyte Kaubriene E, Meskinyte I, Cicenas J, Suziedelis K. Non-Coding RNAs in Glioma. Cancers (Basel). 2018;11:pii: E17. [PMID: 30583549 DOI: 10.3390/cancers11010017] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 12.5] [Reference Citation Analysis]
17 Kadonosono T, Yimchuen W, Tsubaki T, Shiozawa T, Suzuki Y, Kuchimaru T, Sato Y, Kizaka-Kondoh S. Domain architecture of vasohibins required for their chaperone-dependent unconventional extracellular release. Protein Sci 2017;26:452-63. [PMID: 27879017 DOI: 10.1002/pro.3089] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
18 Miyake H, Tanabe K, Tanimura S, Nakashima Y, Morioka T, Masuda K, Sugiyama H, Sato Y, Wada J. Genetic Deletion of Vasohibin-2 Exacerbates Ischemia-Reperfusion-Induced Acute Kidney Injury. Int J Mol Sci 2020;21:E4545. [PMID: 32604722 DOI: 10.3390/ijms21124545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Sanchez-Pulido L, Ponting CP. Vasohibins: new transglutaminase-like cysteine proteases possessing a non-canonical Cys-His-Ser catalytic triad. Bioinformatics 2016;32:1441-5. [PMID: 26794318 DOI: 10.1093/bioinformatics/btv761] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
20 Song W, Yan D, Wei T, Liu Q, Zhou X, Liu J. Tumor-derived extracellular vesicles in angiogenesis. Biomed Pharmacother 2018;102:1203-8. [PMID: 29710539 DOI: 10.1016/j.biopha.2018.03.148] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
21 Ninomiya Y, Ozawa S, Oguma J, Kazuno A, Nitta M, Kajiwara H, Sato Y. Expression of vasohibin-1 and -2 predicts poor prognosis among patients with squamous cell carcinoma of the esophagus. Oncol Lett 2018;16:5265-74. [PMID: 30250596 DOI: 10.3892/ol.2018.9249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
22 Tu M, Li H, Lv N, Xi C, Lu Z, Wei J, Chen J, Guo F, Jiang K, Song G, Gao W, Miao Y. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2. Mol Cancer 2017;16:66. [PMID: 28327155 DOI: 10.1186/s12943-017-0619-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
23 Inoue C, Miki Y, Saito-Koyama R, Kobayashi K, Seyama K, Okada Y, Sasano H. Vasohibin-1 and -2 in pulmonary lymphangioleiomyomatosis (LAM) cells associated with angiogenic and prognostic factors. Pathol Res Pract 2022;230:153758. [PMID: 35026646 DOI: 10.1016/j.prp.2022.153758] [Reference Citation Analysis]